Saniona
Ballerup
About Saniona
Saniona is a pharmaceutical company focusing on the development and advancement of multiple potential new medicines through clinical trials. The company is pioneering in the development of highly selective ion channel modulators. Ion channel modulation is a well-established approach to disease treatment that has been used in medications for diabetes, hypertension, epilepsy, and other conditions. TesometTM, the company's most advanced product candidate, has advanced to mid-stage clinical trials for rare eating disorders. Saniona is advancing two product candidates, SAN711 and SAN903, using its ion channel expertise. A Phase 1 clinical trial of SAN711 for the treatment of neuropathic pain conditions was completed successfully. SAN903 is now ready for Phase 1 clinical trials to treat inflammatory and fibrotic disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $84.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2020)
- Ticker: nasdaq:SANION
- Website: saniona.com
- Phone: +45 70 705 225
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/saniona-130196 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.